Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J.V. McMurray, Hertzel C. Gerstein, Rury R. Holman, et al.
The Lancet Diabetes & Endocrinology (2014) Vol. 2, Iss. 10, pp. 843-851
Closed Access | Times Cited: 289

Showing 1-25 of 289 citing articles:

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer, Brian Claggett, Rafael Díaz, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 23, pp. 2247-2257
Open Access | Times Cited: 2032
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, et al.
The Lancet (2018) Vol. 392, Iss. 10157, pp. 1519-1529
Open Access | Times Cited: 1468
Type 1 diabetes mellitus
Anastasia Katsarou, Soffia Guðbjörnsdóttir, Araz Rawshani, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 1147
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani, Araz Rawshani, Stefan Franzén, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 15, pp. 1407-1418
Open Access | Times Cited: 1064
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
David Fitchett, Bernard Zinman, Christoph Wanner, et al.
European Heart Journal (2016) Vol. 37, Iss. 19, pp. 1526-1534
Open Access | Times Cited: 855
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma, John J.V. McMurray
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2108-2117
Open Access | Times Cited: 790
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica, Eugene Braunwald, Itamar Raz, et al.
Circulation (2014) Vol. 130, Iss. 18, pp. 1579-1588
Closed Access | Times Cited: 687
The changing face of diabetes complications
Edward W. Gregg, Naveed Sattar, Mohammed K. Ali
The Lancet Diabetes & Endocrinology (2016) Vol. 4, Iss. 6, pp. 537-547
Closed Access | Times Cited: 535
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
Petar Seferović, Walter J. Paulus
European Heart Journal (2015) Vol. 36, Iss. 27, pp. 1718-1727
Open Access | Times Cited: 485
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death
Matthew A. Cavender, Philippe Gabríel Steg, Sidney C. Smith, et al.
Circulation (2015) Vol. 132, Iss. 10, pp. 923-931
Open Access | Times Cited: 465
Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders
Bernadette Biondi, George J. Kahaly, R. P. Robertson
Endocrine Reviews (2019) Vol. 40, Iss. 3, pp. 789-824
Open Access | Times Cited: 428
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 5, pp. 665-675
Open Access | Times Cited: 373
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, et al.
Diabetes Care (2017) Vol. 41, Iss. 1, pp. 14-31
Open Access | Times Cited: 350
Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction
Søren Lund Kristensen, David Preiss, Pardeep S. Jhund, et al.
Circulation Heart Failure (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 339
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferović, Brian Claggett, Sara B. Seidelmann, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 5, Iss. 5, pp. 333-340
Open Access | Times Cited: 317
The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease
John R. Ussher, Sammy Elmariah, Robert E. Gerszten, et al.
Journal of the American College of Cardiology (2016) Vol. 68, Iss. 25, pp. 2850-2870
Closed Access | Times Cited: 311
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, J. B. McLaren, Søren Lund Kristensen, et al.
Diabetologia (2016) Vol. 59, Iss. 7, pp. 1333-1339
Open Access | Times Cited: 296
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Rury R. Holman, Ruth L. Coleman, Juliana C.N. Chan, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 5, Iss. 11, pp. 877-886
Open Access | Times Cited: 290
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Richard E. Gilbert, Henry Krum
The Lancet (2015) Vol. 385, Iss. 9982, pp. 2107-2117
Closed Access | Times Cited: 273
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
Jacob A. Udell, Matthew A. Cavender, Deepak L. Bhatt, et al.
The Lancet Diabetes & Endocrinology (2015) Vol. 3, Iss. 5, pp. 356-366
Open Access | Times Cited: 240
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
Francesco Cosentino, Christopher P. Cannon, David Z.I. Cherney, et al.
Circulation (2020) Vol. 142, Iss. 23, pp. 2205-2215
Open Access | Times Cited: 211
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
Darren K. McGuire, Frans Van de Werf, Paul W. Armstrong, et al.
JAMA Cardiology (2016) Vol. 1, Iss. 2, pp. 126-126
Open Access | Times Cited: 206
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 15, pp. 1845-1855
Open Access | Times Cited: 201
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley, et al.
American Heart Journal (2018) Vol. 206, pp. 11-23
Open Access | Times Cited: 191
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K. McGuire, John H. Alexander, Odd Erik Johansen, et al.
Circulation (2019) Vol. 139, Iss. 3, pp. 351-361
Open Access | Times Cited: 148
Page 1 - Next Page

Scroll to top